Defining the Molecular and Radiologic Phenotype of Progressive RA Interstitial Lung Disease

Description

A study to identify patients with Rheumatoid Arthritis - Associated Interstitial Lung Disease (RA-ILD) that are at the highest risk for progression. The goal of the investigators is to recruit a group of patients with RA-ILD and collect information to help us understand more about disease progression. The investigators will do this using a combination of clinical, radiologic, and biologic features.

Conditions

Rheumatoid Arthritis, Interstitial Lung Disease

Study Overview

Study Details

Study overview

A study to identify patients with Rheumatoid Arthritis - Associated Interstitial Lung Disease (RA-ILD) that are at the highest risk for progression. The goal of the investigators is to recruit a group of patients with RA-ILD and collect information to help us understand more about disease progression. The investigators will do this using a combination of clinical, radiologic, and biologic features.

Defining the Molecular and Radiologic Phenotype of Progressive RA Interstitial Lung Disease (MOUNTAIN)

Defining the Molecular and Radiologic Phenotype of Progressive RA Interstitial Lung Disease

Condition
Rheumatoid Arthritis
Intervention / Treatment

-

Contacts and Locations

San Francisco

University of California San Francisco, San Francisco, California, United States, 94143

Aurora

University of Colorado Denver, Aurora, Colorado, United States, 80045

Kansas City

University of Kansas, Kansas City, Kansas, United States, 66103

Ann Arbor

University of Michigan, Ann Arbor, Michigan, United States, 48109

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Multidisciplinary diagnosis of RA-ILD based on the 2010 American College of Rheumatology criteria
  • * 18 years of age or older
  • * Prior medication treatment specifically for RA-ILD
  • * Inability to give informed consent
  • * Pregnant women

Ages Eligible for Study

18 Years to 90 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

University of Colorado, Denver,

Joyce S Lee, PRINCIPAL_INVESTIGATOR, University of Colorado, Denver

Study Record Dates

2034-01